Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II.
Severe mucopolysaccharidosis type II (MPS II) is a progressive lysosomal storage disease caused by mutations in the IDS gene, leading to a deficiency in the iduronate-2-sulfatase enzyme that is involved in heparan sulphate and dermatan sulphate catabolism. In constitutive form, MPS II is a multi-sys...
Main Authors: | Hélène F E Gleitz, Claire O'Leary, Rebecca J Holley, Brian W Bigger |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5313159?pdf=render |
Similar Items
-
Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
by: Hélène FE Gleitz, et al.
Published: (2018-07-01) -
Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
by: Arunabha Ghosh, et al.
Published: (2019-06-01) -
Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
by: Fiona L Wilkinson, et al.
Published: (2012-01-01) -
Haematopoietic stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA
by: Helen Parker, et al.
Published: (2020-03-01) -
Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
by: Chaitanya Gadepalli, et al.
Published: (2021-07-01)